Reversal of Direct Oral Anticoagulants: Guidance from the Anticoagulation Forum

The direct oral anticoagulants (DOACs) comprise the direct thrombin inhibitor, dabigatran, and the direct factor Xa inhibitors, apixaban, betrixaban, edoxaban, and rivaroxaban. Collectively, these agents have been approved by the United States Food and Drug Administration (US FDA) for prevention of stroke and systemic embolism in non-valvular atrial fibrillation, prevention and treatment of ven…

Non–ST-Segment Acute Coronary Syndromes

Edition

-

ISBN/ISSN

-

Collation

-

Series Title

-

Call Number

-

Guidelines on the diagnosis and management of acute pulmonary embolism

Guidelines and Expert Consensus Documents summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategies for a typical patient, suffering from a given condition, taking into account the impact on outcome, as well as the risk/benefit ratio of particular diagnostic or therapeutic means. Guidelines ar…

Variant ECG pattern associated with acute proximal left anterior descending o…

Primary percutaneous coronary intervention is the gold-standard treatment for acute coronary artery occlusion. This is primarily diagnosed by ST segment elevation on an ECG accompanying ischaemic-sounding chest pain.

Complete blood count parameters in peripheral arterial disease

The groups were statistically similar with regards to baseline clinical and demographic features. The values of C-reactive protein, white blood cell and neutrophil-to-lymphocyte ratio values were found to be statistically significantly higher in study group versus control group, but none of them were considered as an independent predictor of peripheral arterial disease according to multivar…

Peripheral Arterial Disease

Peripheral arterial disease (PAD) is a chronic atherosclerotic process that causes narrowing of the peripheral arterial vasculature, predominantly of the lower limbs. It has an estimated worldwide prevalence of up to 10%, increasing to nearly 30% in patients more than 50 years of age.1 Critical limb ischemia (CLI), the most severe manifestation of the disease, can result in limb loss, or even …

The safety of antithrombotic therapy in patients with cerebral microbleeds an…

The impact of cerebral microbleeds on the safety of antithrombotic therapy has recently received considerable attention. We investigated the safety of antithrombotic therapy in patients with cerebral microbleeds and cardiogenic cerebral embolism caused by nonvalvular atrial fibrillation

Fondaparinux in Acute Coronary Syndromes

Anticoagulant therapy is a major component in the management of acute coronary syndromes (ACS). Anticoagulant-associated adverse events like heparin-induced thrombocytopenia, bleeding complications and need of close monitoring of anticoagulation led to focus on developing agents causing anticoagulation without affecting primary haemostasis. Fondaparinux, a new-age synthetic anticoagulant, acts…

The use of fondaparinux in pregnancy

Venous thromboembolism (VTE) remains a major cause of morbidity and mortality in pregnancy. Although relatively safe, hypersensitivity reactions to low-molecular weight heparins (LMWHs) are frequently seen in pregnant women, with a reported 20% incidence in this cohort (Bank et al, 2003; Schindewolf et al, 2013). Fondaparinux is a synthetic pentasaccharide that has been extensively studied in…

Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes

The combined use of anticoagulants, antiplatelet agents, and invasive coronary procedures reduces ischemic coronary events but also increases bleeding in patients with acute coronary syndromes. We therefore assessed whether fondaparinux would preserve the anti-ischemic benefits of enoxaparin while reducing bleeding